Short Bowel Syndrome Market - Forecast(2024 - 2030)

Short Bowel Syndrome Market size is valued at $752m in 2019, and is anticipated to grow at a CAGR of 23.3% during the forecast period 2020-2025. The Short Bowel Syndrome Market growth rate is attributed to the increasing public awareness about the generic disorders or bowel related disorders is influencing the vendors and authorities to provide adequate knowledge. Short bowel syndrome is a group of problems related to poor absorption of nutrients. Short bowel syndrome typically occurs in people who have had at least half of their small intestine removed and sometimes all or part of their large intestine removed, significant damage of the small intestine, poor motility, or movement, inside the intestines. The main symptom of short bowel syndrome is diarrhea—loose, watery stools, which can lead to dehydration, malnutrition, and weight loss. From the initiates by many government bodies, pharmaceutical companies, health ministries, and NGOs conduct health programs and camps to educate the people and raise awareness to the market players distributing free samples and kits with the aim of educating the people and promoting their drugs is anticipated to propel the Short Bowel Syndrome Market during the forecast period 2020-2025.   

The report: “Short Bowel Syndrome Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Short Bowel Syndrome Market:

By Drug Type: GLP-2, Glutamine, Zorbtive, Teduglutide and Others.

By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures and Others.

By Treatment: Nutritional Therapy, Medications, Surgery, Transplant.

By Mode of Administration: Parenteral Administration and Oral Administration.

By Distribution Channel: Hospitals, Diagnostics Centers/Multispecialty Clinics, Hospital/Retail Pharmacies, and Others.

By Geography: North America, Europe, Asia-Pacific and RoW.

GLP-2 drug held the largest share in the market owing to the only products available for treatment with the brand names Gattex, introduced by Takeda which was approved for sales in both the US and Europe respectively. Apart from this, the drugs currently hold the orphan drug status, and the exclusivity of the drugs in the treatment of the short bowel syndrome would further draw huge revenue during the forecast period 2020-2025. The segment is poised to grow at CAGR of 20.4%. Furthermore, the preference by the patients owing to unaffordability and higher expensive parenteral nutrition along with prescription products.

   

Parenteral Administration segment held the largest share in the market owing to less cost associated with hospitalization. Also this method is preferred over oral mode owing to ease of administration, rising preference for home care and reduced duration of treatment. Moreover, the associated benefits of this route of administration includes low risk of systemic infection and improved quality of life.

North America dominated the Short Bowel Syndrome Market with a share of 36% in 2019. The application of Short Bowel Syndrome has grown rapidly over the last few years owing to   rise in the sedentary lifestyle that led no time to focus on nutritious and healthy food with increased consumption of unhealthy and junk food, resultant intestinal disorders continues to expand its market. The research grants by the public & private players in the US to fuel the R&D of SBS drugs are to cater the Short Bowel Syndrome Market in the forecast period of 2020-2025. Moreover, the uncontrolled consumption of antibiotics and the recent research activities and investments on R&D in the region of Asia-Pacific is anticipated to bolster the SBS market growth.

With the rise in demand of various drugs, there are various drugs in clinical development pipeline consists of several first-in-class drugs that are effective and safe for short bowel syndrome patients. And as these drugs gets launched, Strong pipeline drugs for short bowel syndrome they can act as a key driver of the market during the forecast period 2020-2025. 

The major challenge for the market is the side effects of taking drugs that help in the treatment of short bowel syndrome. The most common effects on the health by Revestive or Gattex include cold, nausea, flu, abdominal pain, and headaches. In addition to this it has been found that these medicines can further cause complications in the body such as blockage of the bowel, abnormal cell growth which could for the lead to cancer, polyps in the colon, and inflammation of the gallbladder or blockage of the pancreas. 

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Short Bowel Syndrome Market. In 2019, Short Bowel Syndrome Market share is fragmented by the top ten players present in the market. Short Bowel Syndrome Market top 10 companies are Merck KGaA, Pfizer Inc., Zealand Pharma A/S, Sancilio & Company, Inc., OxThera, Nutrinia Ltd., Ardelyx, Inc., Shire plc (Takeda Pharmaceutical Company Limited), Naia Pharmaceuticals, Inc. and others.